A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

• Status: COMPLETED
• Trial end date: 2024-08-20

Summary

The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide, midazolam and bupropion (i.e. sensitive CYP2C8, CYP3A4 and CYP2B6 substrates).

• Phase: PHASE1

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Bupropion; Midazolam; repaglinide